European Commission approves nivolumab plus ipilimumab as first-line treatment for unresectable malignant pleural mesothelioma

Decision is based on CheckMate -743 trial which met primary endpoint, showing superior overall survival versus chemotherapy (pemetrexed and cisplatin or carboplatin) in all randomised patients (18.1 vs. 14.1 months; HR 0.74, 96.6% CI 0.60-0.91; p=0.002).

Biospace Inc.